...
首页> 外文期刊>BMC Pulmonary Medicine >Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR
【24h】

Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR

机译:使用液滴数字PCR检测痰肺腺癌EGFR突变

获取原文
   

获取外文期刊封面封底 >>

       

摘要

It is still unclear whether epidermal growth factor receptor (EGFR) mutation of primary lung adenocarcinoma can be detected on sputum samples. This study aimed to examine EGFR mutations of primary lung adenocarcinoma in sputum samples using droplet digital polymerase chain reaction (ddPCR) and compare it with an EGFR mutation in surgically resected lung cancer. Sputum was prospectively collected from the patients before complete resection of the primary lung cancer at Kanagawa Cancer Center from September 2014 to May 2016. ddPCR was performed to detect EGFR exon 21 L858R point mutation (Ex21) and EGFR exon 19 deletion mutation (Ex19) in sputum samples from patients with lung adenocarcinoma. The concordance of EGFR mutation status in sputum samples and tumors in surgically resected specimen was evaluated for each positive and negative cytology group. One hundred and eighteen patients with primary lung adenocarcinoma provided sputum samples. Sputum cytology was positive in 13 patients (11.0%). ddPCR detected two cases of Ex21 and two cases of Ex19 in sputum cytology positive cases. Compared to surgically resected specimens, the sensitivity, specificity, and positive predictive value of EGFR mutation (Ex19 and Ex21) detection were 80.0%, 100%, and 100%, respectively, in sputum cytology positive cases. In contrast, the sensitivity, specificity, and positive predictive value of EGFR mutation (Ex19 and Ex21) detection were 3.1%, 100%, and 100%, respectively, in sputum cytology negative cases. EGFR mutations in primary lung adenocarcinoma can be detected with high sensitivity in sputum samples if sputum cytology is positive.
机译:目前还不清楚初生肺癌的表皮生长因子受体(EGFR)突变是否可以在痰样品上检测到。本研究旨在使用液滴数字聚合酶链反应(DDPCR)来研究痰样品中原发性肺腺癌的EGFR突变,并将其与外科肺癌中的EGFR突变进行比较。从2014年9月到2016年5月,在Kanagawa癌症中心的原发性肺癌中完全切除患者前瞻性地收集痰。进行DDPCR以检测EGFR外显子21L858R点突变(EX21)和EGFR外显子19缺失突变(EX19)来自肺腺癌患者的痰样品。对痰液样品和肿瘤在手术切除标本中的EGFR突变状态的一致性被评价每个阳性和阴性细胞学组。一百十八患者原发性肺腺癌患者提供了痰样品。痰细胞学在13名患者中阳性(11.0%)。 DDPCR在痰细胞学阳性病例中检测到两种EX21和两种EX19案例。与手术切除的样本相比,EGFR突变(EX19和EX21)检测的敏感性,特异性和阳性预测值分别为80.0%,100%和100%,分别在痰细胞学阳性情况下。相反,EGFR突变(EX19和EX21)检测的灵敏度,特异性和阳性预测值分别在痰细胞学阴性阴性病例中分别为3.1%,100%和100%。如果痰细胞学是阳性,可以在痰液样品中以高灵敏度检测原发性肺腺癌中的EGFR突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号